Ng CH - Search Results

1

Concordance between actual and pharmacogenetic predicted desvenlafaxine dose needed to achieve remission in major depressive disorder: a 10-week open-label study.

Bousman CA, Müller DJ, Ng CH, Byron K, Berk M, Singh AB. Bousman CA, et al. Among authors: ng ch. Pharmacogenet Genomics. 2017 Jan;27(1):1-6. doi: 10.1097/FPC.0000000000000253. Pharmacogenet Genomics. 2017. PMID: 27779571 Free PMC article.

2

The acute effects of kava and oxazepam on anxiety, mood, neurocognition; and genetic correlates: a randomized, placebo-controlled, double-blind study.

Sarris J, Scholey A, Schweitzer I, Bousman C, Laporte E, Ng C, Murray G, Stough C. Sarris J, et al. Hum Psychopharmacol. 2012 May;27(3):262-9. doi: 10.1002/hup.2216. Epub 2012 Feb 7. Hum Psychopharmacol. 2012. PMID: 22311378 Clinical Trial.

3

ABCB1 polymorphism predicts escitalopram dose needed for remission in major depression.

Singh AB, Bousman CA, Ng CH, Byron K, Berk M. Singh AB, et al. Among authors: ng ch. Transl Psychiatry. 2012 Nov 27;2(11):e198. doi: 10.1038/tp.2012.115. Transl Psychiatry. 2012. PMID: 23188198 Free PMC article.

4

Kava for the treatment of generalized anxiety disorder RCT: analysis of adverse reactions, liver function, addiction, and sexual effects.

Sarris J, Stough C, Teschke R, Wahid ZT, Bousman CA, Murray G, Savage KM, Mouatt P, Ng C, Schweitzer I. Sarris J, et al. Phytother Res. 2013 Nov;27(11):1723-8. doi: 10.1002/ptr.4916. Epub 2013 Jan 24. Phytother Res. 2013. PMID: 23348842 Clinical Trial.

5

Psychomotor depressive symptoms may differentially respond to venlafaxine.

Singh AB, Bousman CA, Ng CH, Byron K, Berk M. Singh AB, et al. Among authors: ng ch. Int Clin Psychopharmacol. 2013 May;28(3):121-6. doi: 10.1097/YIC.0b013e32835f1b9f. Int Clin Psychopharmacol. 2013. PMID: 23442739 Free article.

6

Kava in the treatment of generalized anxiety disorder: a double-blind, randomized, placebo-controlled study.

Sarris J, Stough C, Bousman CA, Wahid ZT, Murray G, Teschke R, Savage KM, Dowell A, Ng C, Schweitzer I. Sarris J, et al. J Clin Psychopharmacol. 2013 Oct;33(5):643-8. doi: 10.1097/JCP.0b013e318291be67. J Clin Psychopharmacol. 2013. PMID: 23635869 Clinical Trial.

7

Pharmacogenetic polymorphisms and response to escitalopram and venlafaxine over 8 weeks in major depression.

Ng C, Sarris J, Singh A, Bousman C, Byron K, Peh LH, Smith DJ, Tan CH, Schweitzer I. Ng C, et al. Hum Psychopharmacol. 2013 Sep;28(5):516-22. doi: 10.1002/hup.2340. Hum Psychopharmacol. 2013. PMID: 24014145

8

Antidepressant pharmacogenetics.

Singh AB, Bousman CA, Ng C, Berk M. Singh AB, et al. Curr Opin Psychiatry. 2014 Jan;27(1):43-51. doi: 10.1097/YCO.0000000000000023. Curr Opin Psychiatry. 2014. PMID: 24270480 Review.

9

High impact child abuse may predict risk of elevated suicidality during antidepressant initiation.

Singh AB, Bousman CA, Ng CH, Berk M. Singh AB, et al. Among authors: ng ch. Aust N Z J Psychiatry. 2013 Dec;47(12):1191-5. doi: 10.1177/0004867413510212. Aust N Z J Psychiatry. 2013. PMID: 24280998

10

Escitalopram efficacy in depression: a cross-ethnicity examination of the serotonin transporter promoter polymorphism.

Bousman CA, Sarris J, Won ES, Chang HS, Singh A, Lee HY, Ham BJ, Tan CH, Lee MS, Ng CH. Bousman CA, et al. Among authors: ng ch. J Clin Psychopharmacol. 2014 Oct;34(5):645-8. doi: 10.1097/JCP.0000000000000165. J Clin Psychopharmacol. 2014. PMID: 24943391 Clinical Trial.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

829 results

Search Page

Filters